The Claim
In adults with type 2 diabetes, treatment with survodutide at doses of 1.8 mg or more weekly for 16 weeks results in greater body weight reduction (mean -6.6% to -8.7%) compared to semaglutide 1.0 mg weekly (mean -5.3%).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Survodutide is a medication that leads to more weight loss than semaglutide in adults with type 2 diabetes. People taking 1.8 mg or more of survodutide weekly lost 6.6% to 8.7% of their body weight over 16 weeks, while those on semaglutide 1.0 mg weekly lost 5.3%.
See the scientific wording
Survodutide doses of 1.8 mg or more weekly produce greater bodyweight reduction than semaglutide 1.0 mg weekly in adults with type 2 diabetes over 16 weeks, with mean reductions of -6.6% to -8.7% vs -5.3%.
Survodutide activates two types of receptors in the body: GLP-1 receptors and glucagon receptors. Activating GLP-1 receptors reduces appetite and slows digestion, so you eat less and feel full longer. Activating glucagon receptors increases the body's energy burning, especially by breaking down fat and boosting metabolism. Together, these actions cause more weight loss than activating only GLP-1 receptors, as semaglutide does.
What the research says
1 studyThe study shows that people taking higher doses of survodutide lost more weight (6.6% to 8.7% of their body weight) than those taking semaglutide (5.3%), just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.